Head to Head Survey: Rigetti Computing (NASDAQ:RGTI) & Decision Diagnostics (OTCMKTS:DECN)

Rigetti Computing (NASDAQ:RGTI) and Decision Diagnostics (OTCMKTS:DECN) are both small-cap computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Earnings and Valuation

This table compares Rigetti Computing and Decision Diagnostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigetti Computing	$11.89 million	162.35	-$75.11 million	($0.38)	-26.42
Decision Diagnostics	N/A	N/A	N/A	N/A	N/A

Decision Diagnostics has lower revenue, but higher earnings than Rigetti Computing.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Rigetti Computing and Decision Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigetti Computing	0	0	5	0	3.00
Decision Diagnostics	0	0	0	0	0.00

Rigetti Computing presently has a consensus target price of $4.80, suggesting a potential downside of 52.19%. Given Decision Diagnostics’ higher possible upside, analysts clearly believe Decision Diagnostics is more favorable than Rigetti Computing.

Institutional and Insider Ownership

35.4% of Rigetti Computing shares are held by institutional investors. 2.8% of Rigetti Computing shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Rigetti Computing and Decision Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rigetti Computing	-509.58%	-51.56%	-37.78%
Decision Diagnostics	N/A	N/A	N/A

Volatility & Risk

Rigetti Computing has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Decision Diagnostics has a beta of -1.53, suggesting that its share price is 253% less volatile than the S&P 500.

Summary

Rigetti Computing beats Decision Diagnostics on 6 of the 10 factors compared between the two stocks.

About Rigetti Computing

Rigetti Computing, Inc., through its subsidiaries, builds quantum computers and the superconducting quantum processors. The company offers cloud in a form of quantum processing unit, such as 9-qubit chip and Ankaa-2 system under the Novera brand name; and sells access to its quantum computers through quantum computing as a service. It also provides quantum cloud services that provides various range of support in programming, public or private clouds integration, and connectivity, as well as quantum operating system software that supports both public and private cloud architectures. In addition, the company offers professional services, such as algorithm development, benchmarking, quantum application programming, and software development. The company serves commercial enterprises, government organizations, and international government entities. It has operations in the United States and the United Kingdom. Rigetti Computing, Inc. was founded in 2013 and is headquartered in Berkeley, California.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.